Scholarlink

Background <p>Due to its unique localization, primary central nervous system (CNS) lymphoma is a&#xa0;special subtype of non-Hodgkin lymphoma. Without treatment, patients die within a&#xa0;short time. Currently, immunochemotherapy followed by consolidative high-dose chemotherapy (if possible) and subsequent autologous stem cell transplant represents the standard of care in eligible patients.</p> Objective <p>This study aims to assess the relevance of high-dose chemotherapy followed by autologous stem cell transplant for treatment of primary CNS lymphoma.</p> Materials and methods <p>The work comprises an assessment of published clinical trials evaluating high-dose chemotherapy followed by autologous stem cell transplant for primary CNS lymphoma, including a&#xa0;discussion of the results, an outlook, and expert recommendations.</p> Results <p>High-dose chemotherapy followed by autologous stem cell transplant as consolidation therapy after methotrexate-based immunochemotherapy is associated with the most favorable prognosis. Due to reduced-intensity induction and conditioning regimens, its application in elderly patients has increased recently. As a&#xa0;cause of potentially severe complications, future clinical trials should aim at reducing toxicities while maintaining efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stellenwert der Hochdosischemotherapie bei der Therapie primärer Lymphome des zentralen Nervensystems

  • 期刊论文

  • 发表日期：

    2025年4月9日

查看全文
  • Gerald Illerhaus,
  • Jan-Michel Heger

摘要

Background

Due to its unique localization, primary central nervous system (CNS) lymphoma is a special subtype of non-Hodgkin lymphoma. Without treatment, patients die within a short time. Currently, immunochemotherapy followed by consolidative high-dose chemotherapy (if possible) and subsequent autologous stem cell transplant represents the standard of care in eligible patients.

Objective

This study aims to assess the relevance of high-dose chemotherapy followed by autologous stem cell transplant for treatment of primary CNS lymphoma.

Materials and methods

The work comprises an assessment of published clinical trials evaluating high-dose chemotherapy followed by autologous stem cell transplant for primary CNS lymphoma, including a discussion of the results, an outlook, and expert recommendations.

Results

High-dose chemotherapy followed by autologous stem cell transplant as consolidation therapy after methotrexate-based immunochemotherapy is associated with the most favorable prognosis. Due to reduced-intensity induction and conditioning regimens, its application in elderly patients has increased recently. As a cause of potentially severe complications, future clinical trials should aim at reducing toxicities while maintaining efficacy.